Zohydro ER Faces FDA Rejection

.

Zohydro ER Faces FDA Rejection

The Food and Drug Administration (FDA) is now opposing the Zohydro ER made by Zogenix Inc. which is stronger and new version of hydrocodone.

The drug was voted very low i. e. 11-2 with one nonparticipation. FDA received the suggestion of government pain expert panel over their rejection since the painkiller was reported to cause high levels of abuse.

Zogenix Inc. is based San Diego who developed the Zohyro ER capsules to cure average to chronic pains. The rejection has emerged as a vital setback for the drug maker since the trades of the drug have been stopped in wake of the news.

However, the FDA will make a final decision about the drug in March 2013 when it will tell whether the drug is safe for use. And if the drug gets the nod from the health officials, US will get its first pure hydrocodone painkiller while those in market as of now are of lower strength.

"There is a documented patient need for an extended-release hydrocodone medicine without acetaminophen. We remain confident in the measures we have proposed to support safe use of Zohydro ER", said Stephen Farr, the President and Chief Operating Officer of Zogenix.

The drugs with hyrocodone and other combinations come under Schedule III drugs while Zohydro ER shall be classified as schedule II drug as it is more powerful.


Latest News

Staples to see Protests from Postal Workers
Even Though Boeing Profit’s Fall by 12.7%
It’s Time for a makeover for Ronald McDonald
Stockpiles Scale in U.S but Brent Steady
Qualcomm’s Growth in China Slowed as Customers Wait for New Technology
Mark Pincus Withdraws from Operations of Zynga Amid Restructuring Plans
Kiwi Rises as RBNZ Hikes Interest Rates
Housing Supply Less Than Home Buyer Demand
GE Plans to Bid for Alstom
Valeant Gains Following Takeover Bid But Slips Again
Abortion-rights advocates condemn mid-pregnancy abortion ban
Californian mother reaches settlement over breast milk dispute with TSA